Pfizer Inc (PFE)
24.89
+0.09
(+0.36%)
USD |
NYSE |
Nov 18, 15:15
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 141.05B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -12.85% |
| Valuation | |
| PE Ratio | 33.64 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.384 |
| Price to Book Value | 1.528 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.42 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7219 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 54.78% |
Profile
| Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor. |
| URL | https://www.pfizer.com |
| Investor Relations URL | https://investors.pfizer.com |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 30, 2025 (est.) |
| Last Earnings Release | Oct. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 08, 2024 |
Ratings
Profile
| Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor. |
| URL | https://www.pfizer.com |
| Investor Relations URL | https://investors.pfizer.com |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 30, 2025 (est.) |
| Last Earnings Release | Oct. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 08, 2024 |